View allAll Photos Tagged ImmuneSystem
A month or so ago I noticed that Gunner was peeing blood. Then purple and red blotches began showing up underneathe his skin (later discovered to be internal bleeding.). He also had a nosebleed and bloody stool. My little one was bleeding out of every hole.
Immune-mediated thrombocytopenia is when platelets are destroyed by the body's own immune system, at a rate faster than they are produced in the bone marrow.
About half of dogs with IMT experience only one episode of thrombocytopenia, and respond well to treatment within a few days. Some dogs will have occasional relapses, which may be associated with stressors such as another illness, or travel. Unfortunately some dogs with this disorder die acutely because of severe internal bleeding.
Thankfully Gunner was the lucky half that has only had one bout of IMT. He started feeling and looking much better after a round of corticosteroids. Sadly for me, I am now afraid to take Gunner new places or on vacation, or leave him alone for long periods of time in fear of him stressing out so much that he has another bout of IMT.
Cora’s Story—Written by Her Mother, Kristine
“We later learned about a type of screening―pulse oximetry―that might have helped identify Cora’s heart defect before it was too late.”
After a healthy and normal pregnancy, I gave birth to my daughter, Cora, on November 30, 2009. Two days later we took her home, after getting a clean bill of health at the hospital. The next 3 days were spent cuddling, getting to know each other, and waking every few hours to feed her.
One early morning my husband handed Cora over to me because she seemed hungry. I started to feed her and everything was going great. I looked up at my husband to tell him I loved him. When I looked back down, Cora was pale, grey, and not breathing. We raced to the hospital, which was no more than 5 minutes away, but it was too late. Cora was gone. We learned from the coroner that she had an undetected congenital heart defect. Neither of us had ever even heard the term.
We later learned about a type of screening―pulse oximetry―that might have helped identify Cora’s heart defect before it was too late. While we’ll never know for sure if it would have made a difference for Cora, we sure wish she’d had the simple screening. Cora’s story is extremely sad, but it’s also full of hope. In Indiana, where we live, a new law requiring newborn heart screening with pulse oximetry is named after her and is known as Cora’s Law.
As for now, I hope for a day when no mother finds out about her child’s heart defect from a coroner. I hope that undetected congenital heart disease becomes a thing of the past. And, ultimately, I hope that one day congenital heart disease can be prevented and that no baby is born with a broken heart.
Learn more about newborn screening:
Disclaimer: Linking to a non-federal site does not constitute an endorsement by CDC, HHS, or any of its employees of the sponsors or the information and products presented on the site.
www.cdc.gov/features/ScreeningNewborns/
www.cdc.gov/spanish/especialesCDC/PruebasRecienNacidos/
www.cdc.gov/ncbddd/pediatricgenetics/newborn_screening.html
www.cdc.gov/ncbddd/pediatricgenetics/CCHDscreening.html
www.cdc.gov/labstandards/nsqap.html
www.cdc.gov/ncbddd/hearingloss/index.html
www.cdc.gov/features/sicklecelldisease/
Joint tissue from patients with rheumatoid arthritis (RA) contains high numbers
of B cells (white), the antibody-producing cells of the immune system. These cells produce high levels of the signaling molecule RANKL (green), which stimulate osteoclasts (red), causing bone to break down. Researchers aim to identify the specific B cell subsets and molecular pathways involved in the cells’ harmful effects so that they can find ways to target them selectively. The ultimate goal is to develop new RA treatments with fewer unwanted side effects.
Credit: Jennifer Anolik, M.D., Ph.D., University of Rochester
Funded by: National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health
Retinitis pigmentosa is an incurable and unpreventable blinding eye disease that affects 1 in 4,000 people.
A new study shows that the complement system, part of the innate immune system, plays a protective role to slow retinal degeneration in a mouse model of retinitis pigmentosa, an inherited eye disease. This surprising discovery contradicts previous studies of other eye diseases suggesting that the complement system worsens retinal degeneration. The research was performed by scientists at the National Eye Institute (NEI), part of the National Institutes of Health, and appears in the Journal of Experimental Medicine.
Read more: www.nih.gov/news-events/news-releases/immune-system-can-s...
In this image: Retinal sections from a patient with retinitis pigmentosa show microglia (green) migrating into the photoreceptor layer (blue) once degeneration had begun. Inset shows microglia expressing C3 (red), which occurred in the context of photoreceptor degeneration.
Credit: National Eye Institute
When people are reminded of self-discrepancies - the difference between how they would like to see themselves and how they are - immune system cells, important for protecting against disease, decrease.
(Strauman, Lemieux & Coe, 1993)
CC image courtesy of: www.flickr.com/photos/thp365/2652739456/
This resource is from the Supercytes website - www.ed.ac.uk/supercytes
Copyright © Donald J. Davidson, University of Edinburgh 2017 CC BY-NC-SA
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
creativecommons.org/licenses/by-nc-sa/4.0/
Supercytes was conceived, designed and developed by Donald J. Davidson, Elena Dorà, Cathy Hawley, Lisa Kelly and Phoebe Kirkwood; all medical research scientists at the University of Edinburgh / MRC Centre for Inflammation Research.
Supercytes artwork was produced by Jim Stirk with graphic design by Gillian Kidd.
www.ed.ac.uk/is/graphic-design
The development of Supercytes was funded by the Wellcome Trust and the Medical Research Council.
This resource is from the Supercytes website - www.ed.ac.uk/supercytes
Copyright © Donald J. Davidson, University of Edinburgh 2017 CC BY-NC-SA
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
creativecommons.org/licenses/by-nc-sa/4.0/
Supercytes was conceived, designed and developed by Donald J. Davidson, Elena Dorà, Cathy Hawley, Lisa Kelly and Phoebe Kirkwood; all medical research scientists at the University of Edinburgh / MRC Centre for Inflammation Research.
Supercytes artwork was produced by Jim Stirk with graphic design by Gillian Kidd.
www.ed.ac.uk/is/graphic-design
The development of Supercytes was funded by the Wellcome Trust and the Medical Research Council.
Von Hippel-Lindau disease, or von Hippel-Lindau syndrome, is a rare genetic disorder characterized by visceral cysts, benign masses, and the potential for malignant transformation in multiple organ systems.
von Hippel–Lindau VHL, the manifestations of the syndrome are protean; therefore, imaging plays a key role in identification of abnormalities and subsequent follow-up of lesions.
von Hippel–Lindau (VHL) disease is a rare, inherited, multisystem disorder that is characterized by development of a variety of benign and malignant tumors.
The spectrum of clinical manifestations of the disease is broad, About 40 different lesions in 14 different organs have been described.
The diagnostic criteria for VHL disease include:
(a) more than one CNS hemangioblastoma,
(b) one CNS hemangioblastoma and visceral manifestations of VHL disease, and
(c) any manifestation and a known family history of VHL disease.
Although genetic testing is available, imaging plays a key role in the identification of abnormalities and their subsequent follow-up, in the screening of asymptomatic gene carriers, and in their long-term surveillance.
The importance of screening is emphasized because the lesions in VHL disease are treatable; thus, early detection enables more conservative therapy to be performed and may enhance the patient’s length and quality of life.
A multidisciplinary approach to screening is emphasized; the team, which is led by a geneticist, includes urologists, gastroenterologists, neurologists, ophthalmologists, and radiologists
Because VHL varies so widely, there is not a consistent set of symptoms in each person. Every incidence of the disease has its own diagnostic evaluation. Being multi -ordinal disorder getting help for treatment of a VHL person is pie in the sky.
My pennyworth experience with VHL
I have been suffering Von Hippel Lindau (VHL) Syndrome since my early childhood. This disorder results in excess blood flow due to hypoxia inducible factor (HIF) resulting in repeated tumor growths in different organs of my body. VHL is a lifetime disease. Patients need to be constantly checked and treated/operated for the tumors and cysts that develop at various sites in the central nervous system and visceral organs throughout their lifetime. Because of the complexities associated with management of the various types of tumours in this disease, treatment is multidisciplinary.
VHL, LIVER TRANSPLANT,MDR-TB , neurologic complications
Very often timely aggressive surgical intervention is the only cure. As a VHL liver transplant patient, I have undergone and 9 surgeries one brain tumor removal, recent cyber knife at Medanta on 18th June 2013 besides grappling with MDR-TB which was diagnosed in 2010.
I developed MDR-TB. Manifestation of my latent TB happened under immune compromised situation, confirmed by a radiological conference facilitated by Dr Randeep Guleria at All India Institute of Medical Sciences (AIIMS). I developed pulmonary, bone and lymph involvement, to such an extent that it gnaws my bones and I walk with help of a four-toed stick.
Why VHL and MDR TB
I often face the question regarding significance of prolonged TB treatment and VHL, as VHL is not directly linked with TB.
Pre- transplant evaluation of Whole Body PET City Scan mentions:
A subcentimetric size lymph node is seen in the right posterior triangle
region which shows markedly increased FDGuptake (1 significance):- dated 21/9/07
8th July 2008:- A tiny non FDG avid, subcentimetre sized, subpleural nodule is noted in the apicoposterior segment of left upper lobe. Compared to previous PET CT, the left lung nodule is a new finding.
Tuberculosis was not detected and my long strife without repository began. Disseminated MDR TB manifested under immunocompromised situation though currently not active.
This is significance of TB aside from VHL, underdiagnosis and lowered immunesystem:- lowered immune system makes it almost impossible to survive the pandemic, I’m lucky to respond but there’s no guarantee it won’t comeback.
Chronological Medical events:
Date of surgery
Site
diagnosis
15/3/1993
Left foot
fibrolipomatous hamartoma (?)cavernous hemangioma
no proper diagnosis
20/12/1994
Right knee
Hamartomatous Malformation(?) cavernous hemangioma / no proper diagnosis
Jan 2005
toncills
Toncillectomy due to multinodular toncills evidence of which remains in multiple nodules in Esophagus in mid and lower third section (definitive inference from the pre-transplant endoscopy performed by Dr.Sanjiv Saigal)
6/2/2006
thyroid
Thyroidectomy 6th Feb 2006 (Multinodular goitre with retrosternal extension and a prominent cavernoma)
8/12/2006
Brain
Craniotomy (haemorrhaged brain tumor) due to cavernous haemangia
6/8/2008
Liver
Liver Transplant due to vascular malformation performed by Dr.A.S.Soin and team with proper diagnosis of VHL
26/7/2009
Left fore-arm
Dr.A.S.Soin removed a cavernous hemangioma from left fore-arm
3/8/2010
. After long painful suffering within 15 days of my Father’s demise on 6/4/2010 in a penniless condition, whatsoever, I survived to know on 3/08/2010 That I got Tuberculosis. Line Probe Assay (HAIN Test) for TB yielded Positive for Mycobacterium tuberculosis( 22/12/2010)
Hence I fell into MDR TB category. This was detected by Dr.Himanshu Garg.
Prior TB treatment was performed by Dr. Sainjiv Saigal with normal prophylactic drugs.
18/july/2011
Cervical lymph gland
Von Hippel Lindau With MDR Kochs cervical lymphadenopathy 20011 at Medanta the Medicity by Dr.K.K . Handa
18/June/2013
Cyber knife Brain
extra dural based well defined nodular lesion adjacent to rt cavernous sinus
Planned for SRS cyber knife to a total dose of 1500cGy to the two lesions, by Dr.Aditya Gupta
The underdiagnosis happened in past as doctors were not well informed.
My general Financial condition:
1. My Father has left nothing, no repository to carryon my treatment
2. We are homeless. I’m living in a crummy rented place with narrow stairs, without ventilation
3. Initial support was provided by my friends and well-wishers but I need support on a larger scale due to multiple problems already narrated
4. Friends and income of younger brother who is a freelancer can no longer pull the economy of my diseases together
5. I’ve no property or any financial assets to pull me through.
Current Situation:-
1. VHL is multidisciplinary, can happen in visceral and Central Nervous System manifestations genetically, which are outwardly not visible. Hence MRI of whole spine and brain/body (CT?) is required -bi annually (as decided by neurosurgeon) Plasma free metaephrines and urinary metaephrines by HPLC method not ELISA method- for tachycardia.
2.Opthalmic by retinal specialist check ups are required(bi- annually)
3.I am Currently undergoing gingival excision and treatment due to initial cyclosporine(immunosuppressant) treatment side-effects.
4.Livertransplant, biannual tests and my current immunosuppressant( Sirolimus) level going up for past year requiring monitoring.
5.CECT of neck and chest/ USG of neck, chest xray often required.
6.Bimonthly LFT,Sirolimus,RFT,CBC
7.Biannual CBC, LFT, Na, K, Bun, Creatinine, Uric Acid,Hb1C, Lipid profile, Chest Xray, Urine Routine/Microscopic, Urine Culture/ sensitivity, Ultrasound whole Abdomen +liver Doppler (MHV showing monophasic flow in the liver graft suddenly from triphasic requiring repeated test for explanation)
All this is Way too expensive for me to bear with my younger brother( 4 yrs younger) being the sole earning member.
My mother is just a pensioner which doesn’t even suffice our accommodation and victuals.
My experience tells me VHL is seldom understood, and discrimination against disease exists. I’m a survivor not sufferer, I guess my strife with a rare disease shall be taken in good stride and help me in my spirited fight against a lifelong disease.
I don’t flinch and Cyber knife now performed, I need to deal with other complexities; but lack of funds and understanding makes the feelings worse. Please help me live the joyous life with a rare disorder as I am a survivor and not merely a sufferer. I’ve not lost the verve to life- help me lead a very happy life with VHL.
“The smallest minority on earth is the individual. Those who deny individual rights cannot claim to be defenders of minorities.”- Hence I appeal to exercise my fundamental right to health of a minority individual being discriminated.
This resource is from the Supercytes website - www.ed.ac.uk/supercytes
Copyright © Donald J. Davidson, University of Edinburgh 2017 CC BY-NC-SA
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
creativecommons.org/licenses/by-nc-sa/4.0/
Supercytes was conceived, designed and developed by Donald J. Davidson, Elena Dorà, Cathy Hawley, Lisa Kelly and Phoebe Kirkwood; all medical research scientists at the University of Edinburgh / MRC Centre for Inflammation Research.
Supercytes artwork was produced by Jim Stirk with graphic design by Gillian Kidd.
www.ed.ac.uk/is/graphic-design
The development of Supercytes was funded by the Wellcome Trust and the Medical Research Council.
Piet oudolf planting at dreampark, enkoping, sweden: Echinacea purpurea 'magnus', scutellaria incana, astilbe chinensis var taquetii 'purpurlanze'
#Yogaposture #wonderfulpose #comfortablepose #Immunesystem #Holisticbenefits; Extend arms like wings, the wonderful pose gives you holistic benefits through stimulating the immune system and aligning the tricky little.
Lady farm, somerset: Backlit flowers of echinacea purpurea rubinstern (Agm) And perovskia blue spire (Russian sage)
Airborne Immune System Supplements , 12/2014 Walmart, by Mike Mozart of TheToyChannel and JeepersMedia on YouTube
Exposure to antigens in vaccines from 1900 to 2000, bar graph, color. Current antigen levels are 4% of the levels for the previous 40 years and lower than at any time since 1900.
Collection:
Images from the History of Medicine (IHM)
Format:
Still image
Related Title(s):
Is part of: Photographs of the Diseases Of The Skin
Extent:
1 photoprint
Technique:
albumen, color
NLM Unique ID:
101434056
NLM Image ID:
A029082
Permanent Link:
This resource is from the Supercytes website - www.ed.ac.uk/supercytes
Copyright © Donald J. Davidson, University of Edinburgh 2017 CC BY-NC-SA
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
creativecommons.org/licenses/by-nc-sa/4.0/
Supercytes was conceived, designed and developed by Donald J. Davidson, Elena Dorà, Cathy Hawley, Lisa Kelly and Phoebe Kirkwood; all medical research scientists at the University of Edinburgh / MRC Centre for Inflammation Research.
Supercytes artwork was produced by Jim Stirk with graphic design by Gillian Kidd.
www.ed.ac.uk/is/graphic-design
The development of Supercytes was funded by the Wellcome Trust and the Medical Research Council.
This resource is from the Supercytes website - www.ed.ac.uk/supercytes
Copyright © Donald J. Davidson, University of Edinburgh 2017 CC BY-NC-SA
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
creativecommons.org/licenses/by-nc-sa/4.0/
Supercytes was conceived, designed and developed by Donald J. Davidson, Elena Dorà, Cathy Hawley, Lisa Kelly and Phoebe Kirkwood; all medical research scientists at the University of Edinburgh / MRC Centre for Inflammation Research.
Supercytes artwork was produced by Jim Stirk with graphic design by Gillian Kidd.
www.ed.ac.uk/is/graphic-design
The development of Supercytes was funded by the Wellcome Trust and the Medical Research Council.
Echinacea purpurea 'magnus',calamagrostis acutiflora 'karl forster',aster umbellatus.Tuinen ton ter linden, holland
In the immune system, T helper cells stimulate B cells to produce antibodies that fight potential disease-causing infections. In people with rheumatoid arthritis (RA), however, B cells produce autoantibodies that attack the body’s own healthy tissues. Researchers have identified a specific type of T helper cells, called T peripheral helper (Tph) cells (stained blue). These cells stimulate B cells (green) to produce autoantibodies in the joints of people with RA. Understanding this mechanism may help scientists develop new treatment targets for the disease.
Photographer: Michael B. Brenner, M.D., and Deepak Rao, M.D., Ph.D., Brigham and Women’s Hospital, Boston.
This resource is from the Supercytes website - www.ed.ac.uk/supercytes
Copyright © Donald J. Davidson, University of Edinburgh 2017 CC BY-NC-SA
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
creativecommons.org/licenses/by-nc-sa/4.0/
Supercytes was conceived, designed and developed by Donald J. Davidson, Elena Dorà, Cathy Hawley, Lisa Kelly and Phoebe Kirkwood; all medical research scientists at the University of Edinburgh / MRC Centre for Inflammation Research.
Supercytes artwork was produced by Jim Stirk with graphic design by Gillian Kidd.
www.ed.ac.uk/is/graphic-design
The development of Supercytes was funded by the Wellcome Trust and the Medical Research Council.
Lady farm, somerset: Designer, judy pearce - plant association/ Combination with echinacea rubinstern and perovskia blue spire
ECHINACEA PURPUREA 'RUBY GLOW', ANGELICA GIGAS, ASTRANTIA 'ROMA', VERONICA VIRGINICA 'ALBA'.DESIGN:PIET & ANJA OUDOLF
Killer T cells (green and red) surround a cancer cell (blue, center). Killer T cells are immune cells that target and remove unhealthy cells, including cancer cells and virus-infected cells. Credit: J. Lippincott-Schwartz, NICHD
Piet oudolf planting at dreampark, enkoping, sweden: Echinacea purpurea 'magnus', scutellaria incana, astilbe chinensis var taquetii 'purpurlanze'
This resource is from the Supercytes website - www.ed.ac.uk/supercytes
Copyright © Donald J. Davidson, University of Edinburgh 2017 CC BY-NC-SA
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
creativecommons.org/licenses/by-nc-sa/4.0/
Supercytes was conceived, designed and developed by Donald J. Davidson, Elena Dorà, Cathy Hawley, Lisa Kelly and Phoebe Kirkwood; all medical research scientists at the University of Edinburgh / MRC Centre for Inflammation Research.
Supercytes artwork was produced by Jim Stirk with graphic design by Gillian Kidd.
www.ed.ac.uk/is/graphic-design
The development of Supercytes was funded by the Wellcome Trust and the Medical Research Council.
Isolation
My second try at clone photography after this one.
The peculiarity is that in this second one you can only see my face (completely) with the clone in bed, which is also the only one wearing glasses (but this only I can know:)
On April 14 2007 I was diagnosed with Acute Promyelocitic Leukemia. I have been fighting it for 8 months, surviving a one month coma and a cardiac arrest. In December 2007 I was finally released from the hospital. In June 2008, a bone marrow test showed that my cancer had relapsed and I had to enter the hospital again. I have been in isolation for 5 weeks now, and the new therapy seems to be working. Thanks God.
Isolation is necessary for leukemia patients, as the treatments used to fight it cause temporary immuno-deficiency with high risks for infection.
This image intends to describe that state of isolation by showing what one might end up doing to accelerate time a bit: like reading, exercising, meditating, or working on clones with Photoshop :)
It is estimated that 44,270 men and women will be diagnosed with and 21,710 men and women will die of Leukaemia in 2008 in the U.S. only (respectively 138,530 and 52,910 including Lymphoma and Myeloma figures ->1). Leukaemia is children’s world top killer. (source)
Although research has brought to great achievements, many forms of leukaemia are still not curable or entail therapies that are painful and risky for the patient. Moreover, most of the world’s countries cannot afford the highly expensive drugs needed to beat leukaemia.
We cannot change the past, but we can definitely make a difference in our future. Those who are unconvinced of the benefits of research can look back and acknowledge that until not long ago people died of diseases as innocuous as flu.
More info here.
PICTURE INFO
Multiple self- portrait taken with a Nikon D700 with timer on improvised stand (a pile of books:)
Lens/Focal length: Nikkor 18-135 on 18mm
Exposure: 1/60s - f/3.5
WB: Cool-white fluorescent
ISO: 1250
CONSTRUCTIVE COMMENTS ARE HIGHLY APPRECIATED!!! :))
Collection:
Images from the History of Medicine (IHM)
Format:
Still image
Related Title(s):
Is part of: Photographs of the Diseases Of The Skin
Extent:
1 photoprint
Technique:
albumen, color
NLM Unique ID:
101434050
NLM Image ID:
A029076
Permanent Link:
Collection:
Images from the History of Medicine (IHM)
Publication:
Bethesda, MD : U.S. National Library of Medicine, National Institutes of Health, Health & Human Services, [2010]
Language(s):
English
Format:
Still image
Subject(s):
Face -- pathology
Eczema -- pathology
Genre(s):
Pictorial Works
Abstract:
Stereographies of a man's face with a chronic rash, the excoriations caused by scratching and rubbing alter its appearance. Stereoscopic skin clinic.
Related Title(s):
Hidden treasure and Is part of: Stereoscopic skin clinic.; See related catalog record: 48220640R
Extent:
1 online resource (1 image)
NLM Unique ID:
101601064
NLM Image ID:
A033213
Permanent Link:
The aim of the book is to provide a comprehensive General Practice text book which takes a contemporary, integrative approach to diagnosis, investigation and management of health issues and disease states encountered in the general practice environment. The book covers the philosophy underpinning general practice in the 21st Century, and deals with primary and secondary prevention as well as acute and chronic disease management.
General Practice: The Integrative Approach informs doctors as fully as possible about potential treatment and prevention options, as well as potential pitfalls according to the growing evidence base in this area. The book is directed at best practice rather than alternative practice. The first section of the textbook lays the foundations and principles of Integrative Medicine and the second section examines important medical conditions in a systems based approach.
Each chapter begins by detailing the medical and consulting knowledge required of a standard GP text, discussing physiology and pharmacological management plans of systems-based conditions. The chapter then leads into an evidence-based discussion of the therapeutic options available for the treatment of associated factors, essentially providing practitioners with the knowledge required to adapt their approach to meet the needs of the individual patient.
A national panel of experts with experience in Chinese medicine, herbal medicine, nutritional medicine, naturopathy, and exercise therapy have contributed to their various fields of expertise to incorporate management plans that utilise a variety of therapeutic modalities to achieve the best clinical outcome.
Incorporates evidence-based and safe therapies including conventional medical care, lifestyle interventions, complementary therapies.
Approach is holistic in focus
Focuses on prevention and health promotion
Symptomatic layout matches the approach of contemporary medical curriculum
Each therapeutic modality and therapeutics contributor will be allocated an icon, throughout the book the icon will appear near the corresponding therapeutics text for easy modality reference
Unique chapter – Integrative Medicine and the Law – covering medico-legal issues.
Ready reference herb/drug interaction chart
shop.elsevier.com.au/ISBN/9780729538046/General-Practice/...
Killer T cells are immune cells that find and destroy tumor cells and virus-infected cells.
In this immunofluorescence image, a killer T cell (blue, bottom) is engaging a target cell (center). A patch of signaling molecules (pink) that gathers at the site of cell-cell contact indicates that the killer T cell has identified a target. Lytic granules (red) that contain cytotoxic components travel along the microtubule cytoskeleton (green) to the contact site and are released, thus killing the target cell.
Credit: J. Lippincott-Schwartz, NICHD
Thymus Gland - How Does This Little Known Gland Help Your Immune System?
tampabayinformer.com/Health/Natural-Health/2009/12/14/Thy...
Collection:
Images from the History of Medicine (IHM)
Format:
Still image
Related Title(s):
Is part of: Photographs of the Diseases Of The Skin
Extent:
1 photoprint
Technique:
albumen, color
NLM Unique ID:
101434057
NLM Image ID:
A029083
Permanent Link:
This resource is from the Supercytes website - www.ed.ac.uk/supercytes
Copyright © Donald J. Davidson, University of Edinburgh 2017 CC BY-NC-SA
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
creativecommons.org/licenses/by-nc-sa/4.0/
Supercytes was conceived, designed and developed by Donald J. Davidson, Elena Dorà, Cathy Hawley, Lisa Kelly and Phoebe Kirkwood; all medical research scientists at the University of Edinburgh / MRC Centre for Inflammation Research.
Supercytes artwork was produced by Jim Stirk with graphic design by Gillian Kidd.
www.ed.ac.uk/is/graphic-design
The development of Supercytes was funded by the Wellcome Trust and the Medical Research Council.
Collection:
Images from the History of Medicine (IHM)
Format:
Still image
Extent:
1 photoprint.
NLM Unique ID:
101446738
NLM Image ID:
A017916
Permanent Link:
This resource is from the Supercytes website - www.ed.ac.uk/supercytes
Copyright © Donald J. Davidson, University of Edinburgh 2017 CC BY-NC-SA
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
creativecommons.org/licenses/by-nc-sa/4.0/
Supercytes was conceived, designed and developed by Donald J. Davidson, Elena Dorà, Cathy Hawley, Lisa Kelly and Phoebe Kirkwood; all medical research scientists at the University of Edinburgh / MRC Centre for Inflammation Research.
Supercytes artwork was produced by Jim Stirk with graphic design by Gillian Kidd.
www.ed.ac.uk/is/graphic-design
The development of Supercytes was funded by the Wellcome Trust and the Medical Research Council.